Agilent Technologies Inc vs Chewy Inc — how do they compare? Agilent Technologies Inc trades at $147.9 (market cap $42.22B), while Chewy Inc trades at $22.19 (market cap $9.20B). The key difference: Agilent Technologies Inc is far larger — about 4.6× Chewy Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| A | CHWY | |
|---|---|---|
Market Cap | $42.22B | $9.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $42.33 |
52-Week Low | $110.24 | $17.51 |
Enterprise Value | $43.77B | $9.16B |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.72, up 1.88% with strong analyst support (77.5% buy ratings). The stock shows bullish technical momentum above key support levels, supported by consistent revenue around $6.9B and robust profitability with 19.55% net margins. Recent FDA approvals for diagnostic tests and the Biocare Medical acquisition enhance growth prospects in biopharma markets.
Outlook remains positive with a $154.90 consensus price target offering 4% upside, though high P/E of 30.02 poses valuation risk. Key catalysts include Q2 2026 earnings due August 26 and AI-driven lab expansion, while overbought RSI levels near 92 suggest near-term consolidation potential.
Chewy (CHWY) trades at $22.59, down 3.99% on the day, reflecting near-term bearish technical pressure. The stock shows strong fundamental progress with revenue climbing to $11.86B in 2025 and net income surging to $392.74M, marking a significant profitability turnaround. Recent earnings beats in Q3 2025 and Q1 2026 contrast with a Q4 2025 miss, indicating volatility. Analyst sentiment remains overwhelmingly positive with an 81.58% buy rating and a $33.82 consensus price target, suggesting substantial upside potential from current levels.
The investment outlook for CHWY is constructive, driven by robust revenue growth, expanding margins, and strong analyst conviction. Key opportunities include the company's dominant position in the pet care e-commerce space and its high customer loyalty through the Autoship subscription model. Primary risks involve competitive pressures from larger retailers, execution challenges in integrating veterinary services, and sensitivity to consumer spending trends. The stock presents a growth opportunity but requires monitoring of quarterly execution against high expectations.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →